Related Experiment Video

Updated: Apr 24, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort

Gerald Pierone1, Laurence Brunet2, Jennifer S Fusco2

  • 1Whole Family Health Center, Vero Beach, FL, USA.

Journal of the International Association of Providers of AIDS Care
|April 23, 2026
PubMed

Purpose of the researchTo compare incident hypertension rates across antiretroviral therapy regimens among adults with HIV in routine clinical care in the US-based OPERA cohort.Major findingsThe hypertension incidence rate was 4.16 per 100 person-years (95% CI: 3.75, 4.61) among 3220 ART-naïve individuals, and 4.60 (95% CI: 3.99, 5.30) among 1442 ART-experienced individuals. There was no statistically significant difference in incident hypertension between regimens at the class-level (integrase inhibitor with/without tenofovir alafenamide (TAF), boosted protease inhibitor, and non-nucleoside reverse transcriptase inhibitor) nor the drug-level (dolutegravir three-drug regimen with/without TAF, dolutegravir/lamivudine, bictegravir/emtricitabine/TAF, and boosted darunavir with TAF three-drug regimen).ConclusionsIn this large cohort representing routine clinical care in the USA, classes of antiretrovirals and specific agent combinations with or without TAF were not statistically significantly associated with incident hypertension. Other factors are likely to be more important drivers of hypertension than antiretroviral therapy selection in people with HIV.

Keywords:
antiretroviral therapy (ART)health outcomesintegrase inhibitornon-Nucleoside reverse transcriptase inhibitor (NNRTI)nucleoside reverse transcriptase inhibitor (NRTI)protease inhibitor

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
11.8K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.4K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
553
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K